Should ocrelizumab \u0026 cladribine be treated in the same way as alemtuzumab in terms of COVID-19 risk?

(58:22)

Results of ocrelizumab in treatment-naïve patients with early relapsing MS

(5:20)

Ocrelizumab Use in Treating Multiple Sclerosis

(6:31)

Ocrelizumab: What to Know About the First Agent Approved for Primary Progressive MS

(5:47)

Ocrevus 3 Times A Year?!

(30)

Safely switching from natalizumab to ocrelizumab in patients with MS at risk of PML

(2:14)

How Ocrevus works in Multiple Sclerosis

(3:7)

Ocrevus, Rituxan \u0026 Kesimpta: How They Work and When to Use Them

(10:55)

Risk of B-Cell Depleters Long-Term (Ocrevus, Rituximab, Kesimpta, Briumvi)

(14:28)

June Halper: What Ocrelizumab Has Shown in PPMS

(1:39)

Impact of ocrelizumab disruption on RRMS

(2:52)

How to give Ocrevus...Differently?!

(12:10)

New Drug Could Help Multiple Sclerosis Patients Better Manage Symptoms

(2:4)

Long-term results of ocrelizumab in treatment-naive patients with early relapsing MS

(4:32)

Ocrelizumab Is Safe and Effective in Minority Groups With Multiple Sclerosis

(1:15)

Ocrelizumab, and Treating Primary Progressive Multiple Sclerosis

(2:35)

Ocrelizumab Provides Potential Answer to Difficult Treatment Questions

(5:46)

Role of Ocrelizumab in Europe for Multiple Sclerosis

(6:39)

Early Treatment With Ocrelizumab Yields Better Outcomes in Multiple Sclerosis

(1:48)

Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab

(3:33)